Howard Newman

Howard Newman

Auto-generated profile, based on publicly available information

Howard Newman

National Health Laboratory Service, Port Elizabeth, South Africa and Department of Pathology, Division of Medical Virology, Stellenbosch University, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2013 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
HNHoward Newman
Howard Newman
CGCaroline Gooding
Caroline Gooding

30 May 2019 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
GZGert van Zyl
Gert van Zyl
JMJean Maritz
Jean Maritz
HNHoward Newman
Howard Newman
Wolfgang PreiserWolfgang Preiser
Wolfgang Preiser

25 September 2020 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
HNHoward Newman
Howard Newman
DHDiana Hardie
Diana Hardie

30 August 2017 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
HNHoward Newman
Howard Newman
JMJean Maritz
Jean Maritz

1 August 2014 in Journal of Clinical Virology
Verified
Journal Article
Open access
HNHoward Newman
Howard Newman
LBLukas Breunig
Lukas Breunig
GZGert van Zyl
Gert van Zyl
ASAugust Stich
August Stich
Wolfgang PreiserWolfgang Preiser
Wolfgang Preiser
The high cost of commercial HIV-1 viral load tests for monitoring of patients on antiretroviral treatment limits their use in resource-constrained settings. Commercial genotypic antiretroviral resistance testing is even more costly, yet it provides important benefits. We sought to determine the sensitivity and negative predictive value of a qualitative PCR targeting partial reverse transcriptase for detection of virologic failure when 5 patient specimens are pooled. A total of 300 South African routine patient samples were included and tested in 60 pools of 5 samples each. A qualitative nested PCR was optimised for testing pools and individual samples from positive pools. All positive samples were sequenced to detect drug resistance-associated mutations. Results were compared to those of conventional viral load monitoring. Twenty-two of 60 pools tested positive. Individual testing yielded 29 positive individual samples. Twenty-six patients had viral loads of above 1000 copies/ml. The pooling algorithm detected 24 of those 26 patients, resulting in a negative predictive value of 99.3%, and a positive predictive value of 89.7%. The sensitivity for detecting patients failing therapy was 92%, with a specificity of 98.9%. Of the patients failing first-line ART, 83.3% had NRTI and 91.7% NNRTI resistance mutations. The pooled testing algorithm presented here required 43% fewer assays than conventional viral load testing. In addition to offering a potential cost saving over individual viral load testing, it also provided drug resistance information which is not available routinely in resourced-limited settings.

22 December 2023 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
DHDiana Hardie
Diana Hardie
HNHoward Newman
Howard Newman
JRJoanna Reid
Joanna Reid
NHNei-Yuan Hsiao
Nei-Yuan Hsiao
GZGert van Zyl
Gert van Zyl
SKStephen Korsman
Stephen Korsman
Background: Understanding factors that impact HIV viral load (VL) accuracy in resource-limited settings is key to quality improvement. Objective: We evaluated whether testing delay and specimen storage between 25 °C and 30 °C before testing affected results. Methods: Between November 2019 and June 2023, 249 individuals on antiretroviral therapy, or with newly diagnosed HIV, were recruited from clinics in Cape Town and Gqeberha, South Africa, and three plasma preparation tubes were collected. One tube was tested within 24 h, while the others were stored uncentrifuged at ambient temperatures before testing. Centrifugation and testing of matched samples were performed on Day 4 and Day 7 after collection. Results: Time delay and ambient storage had minimal impact in specimens with a Day 1 VL of > 100 copies/mL. When grouped by Day 1 VL range, 96% – 100% of specimens at Day 4 and 93% – 100% at Day 7 had VLs within 0.5 log copies/mL of the first result. The greatest variability at Days 4 and 7 was observed when the Day 1 VL was < 100 copies/mL. However, there was no trend of increasing difference over time. Of Day 1 specimens with undetectable VL, or VL < 50 copies/mL, 80% had concordant results at Day 4 and 78% at Day 7. Conclusion: These results show that VL is stable in plasma preparation tubes for 7 days when stored at room temperature. There is significant variability in specimens with low VL, but variability is not affected by testing delay. What this study adds: Ideal HIV VL testing conditions are frequently unachievable in resource-limited settings. Data are needed on whether this impacts on the validity of test results. Our results provide reassurance that storage at ambient temperature for up to 7 days before testing does not substantially affect the VL result.